Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D002051:Burkitt Lymphoma / Q000209:etiology / Q000517:prevention & control*; D002143:Callitrichinae; D002648:Child; D002675:Child, Preschool; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007244:Infectious Mononucleosis / Q000276:immunology*; D008297:Male; D051379:Mice; D009303:Nasopharyngeal Neoplasms / Q000209:etiology / Q000276:immunology; D011817:Rabbits; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control*; D014765:Viral Vaccines / Q000627:therapeutic use*
D000954:Antigens, Surface; D000956:Antigens, Viral; D014765:Viral Vaccines